PsychedelicNewsBreaks

MondayApr 26, 2021 10:50 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces AUD Disorder Indication for Psychedelic Molecule CYB003

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the company noted that its CYB003 new chemical entity (“NCE”) could be an ideal investigational new drug (“IND”) candidate for a future clinical trial focused on AUD after preclinical data has been compiled and evaluated. Cybin is targeting an IND filing for CYB003 by the end of this year. AUD is a relapsing brain disorder often associated with an impaired ability to stop or control alcohol…

Continue Reading

WednesdayApr 21, 2021 10:44 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Data Providing Strong Support to Advance Drug Development Candidates

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it has successfully demonstrated proof of concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction. According to the update, the U.S. Food and Drug Administration (“FDA”) has granted breakthrough therapy designation to multiple long-acting psychedelic treatments. However, these potential treatments produce extended psychedelic effects that present challenges to patient access and potentially to payer reimbursement. To overcome these issues, Cybin is working to optimize the duration of action of its treatments through the selective deuteration of several…

Continue Reading

TuesdayApr 20, 2021 9:48 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head of corporate development. An experienced management and finance consultant with impressive exposure to mergers and acquisitions, corporate re-organizations, and divestitures, Probst has a proven track record of leadership, strategic planning and organizational restructuring. In his new position, he will be responsible for managing the company's…

Continue Reading

MondayApr 19, 2021 1:36 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) to Bring Quality Products to Retail Buyers Across Canada

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), through its wholly owned subsidiary, Pure Extracts Manufacturing Corp., recently entered into a distribution agreement with an important Canadian LP. Under the agreement, the LP will sell Pure Extracts’ exclusive, high-quality cannabis extract products to provincially authorized distributors and retailers throughout Canada by the end of April. In addition, Pure Extracts has submitted an application to Health Canada to amend its license to permit the company itself to sell cannabis extract products to provincially authorized distributors and retailers. “This milestone dovetails perfectly with our recently signed distribution agreement,” said Pure Extracts’…

Continue Reading

ThursdayApr 15, 2021 11:38 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs.…

Continue Reading

WednesdayApr 14, 2021 12:19 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Prepares to Commence Retail Sales of Gummie Products

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it has commenced production on approximately 50,000 Pure Chews edible gummie packs. Demand for these types of products is strong in the four provinces (British Columbia, Alberta, Saskatchewan and Ontario) that Pure Extracts is targeting for its retail launch, with approximately $200,000 in revenue estimates associated with this batch. All Pure Chews SKUs, including the 10 mg THC packs of Fire Burst, Strawberry and Mango, utilize a proprietary manufacturing system licensed from…

Continue Reading

TuesdayApr 13, 2021 10:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004. In the announcement, the company noted that the planned studies are part of the required U.S. Food and Drug Administration (“FDA”) enabling trials for investigational new drug applications (“INDs”). The results of the studies will be included in the submissions to the FDA and other regulatory bodies, including Health Canada and European Medical Association (“EMA”). The proprietary Cybin…

Continue Reading

FridayApr 09, 2021 9:23 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Strategic Equity Investment in Psychedelic Journey Center

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology for psychedelic therapy, has announced a follow-up strategic equity investment in ATMC Journey Centers Inc. ("ATMA"), the first government-approved psychedelic journey center in Canada. Earlier this year, MCUR had signed a letter of intent, securing 13% ownership in ATMA; this additional investment retains that ownership. In addition, the company named Mind Cure Health president and CEO Kelsey Ramsden to the ATMA board of directors. MINDCURE’s investment into the pioneering psychedelic journey center is meant to facilitate the use of iSTRYM (“iSTRYM”), which is MCUR’s proprietary…

Continue Reading

ThursdayApr 08, 2021 9:57 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Plans to Launch 1st US Initiative into Dynamic Michigan Market

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced its entry into a letter of intent (“LOI”) with the affiliate of a publicly traded multistate operator (“MSO”) to form a joint venture (the “JV”) to install a cannabis and hemp extraction system in an existing Michigan facility. According to the update, the MSO has a long history of success in Oregon, offering a family of products that include sun-grown and indoor premium flower, along with patented nitro-sealed indoor and sun-grown pre-rolls and…

Continue Reading

WednesdayMar 31, 2021 10:52 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has inked a letter of intent (“LOI”) to form a joint venture (“JV”) with Psyence Group Inc. (CSE: PSYG). The agreement with Psyence, one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa, calls for the development of high-class techniques for the extraction of psilocybin from psychedelic mushrooms as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and…

Continue Reading